| Revision as of 15:52, 10 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 460520610 of page Vepalimomab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 01:40, 9 April 2023 edit Entranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,984 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 447729115 |
|
| verifiedrevid = 470629578 |
|
| image = |
|
| image = |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = o |
|
| source = o |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
| Line 22: |
Line 20: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 29: |
Line 26: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
| ⚫ |
<!--Identifiers--> |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = <!-- blanked - oldvalue: 195158-85-1 --> |
|
| CAS_number = 195158-85-1 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 0M19J59UH4 |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 40: |
Line 38: |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
| chemical_formula = |
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
|
'''Vepalimomab''' is an experimental ] ] intended for the treatment of ]s. It blocks ].<ref>{{cite journal | vauthors = Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T | title = Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis | journal = Basic & Clinical Pharmacology & Toxicology | volume = 96 | issue = 6 | pages = 429–35 | date = June 2005 | pmid = 15910406 | doi = 10.1111/j.1742-7843.2005.pto_05.x | doi-access = free }}</ref> Development of the drug was discontinued in 2002.<ref>{{cite web |title=Vepalimomab | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800016990 | publisher = Springer Nature Switzerland AG }}</ref> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
{{immunosuppressants}} |
|
|
{{Monoclonals for immune system}} |
|
|
|
|
|
] |
|
|
] |
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
|
{{antineoplastic-drug-stub}} |